Life sciences firm Gentronix set for ‘fantastic next step’ after it is acquired by Danish group Scantox

Fast-growing life sciences business Gentronix has been acquired by Danish business Scantox Group in what bosses say is a “fantastic next step” for the company and its 70 staff.

Alderley Park-based Gentronix offers genetic toxicology solutions to the global pharmaceutical, biotech and agrichemical industries. It was founded in 1999 by Prof. Richard Walmsley and Scantox says it has seen “a significant scale-up over the past five years”.

The deal provides an exit for Mercia Ventures’ Northern Venture Capital Trusts which have sold their stake in Gentronix for £14.8m, representing a 4.5x return on investment.

Scantox Group, which has its headquarters in Ejby to the south of Copenhagen, says Gentronix “is well recognised for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base”.

Gentronix will continue under its current name and is set to grow its offering under Scantox, which is itself backed by Scandinavian inves